An interventional study of ShotBlocker in Acute Pain and Anxiety, sponsored by Kirsehir Ahi Evran Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Kirsehir Ahi Evran Universitesi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Acute Pain with a site in Turkey — 23 open to participants now, 26 under way, none of them phase 3. Acute Pain · Turkey.
Among the 158 studies in Acute Pain with a site in Turkey, this one is the 43rd largest by enrollment of the 135 interventional ones that give a count, is one of 15 that started in 2026, is one of 130 with no phase, and was the 148th registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →23 of the 158 studies in Acute Pain with a site in Turkey are open now. Recruiting first, the newest first:
Ankara Etlik City Hospital · Sites in Turkey
Ages 18–65
Bursa City Hospital · Sites in Turkey
Ages 18–45 · Women only
Akdeniz University · Sites in Turkey
Ages 6–12 · Healthy volunteers
Harran University · Sites in Turkey
Ages 18–65
Atatürk Chest Diseases and Chest Surgery Training and Research Hospital · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 86 across 905 interventional studies indexed under Acute Pain.
Median enrollment 80 across the 135 interventional studies, 87 across the 23 observational. Of the 122 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 158 has an industry lead sponsor. The 10 most frequent:
Kirsehir Ahi Evran Universitesi is the lead sponsor of 142 studies on the registry; 55 are open to participants now.
Kirsehir Ahi Evran Universitesi has 1 study filed under Acute Pain — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07683663Dokuz Eylul UniversityQIPB vs SI-FICB for Postoperative Analgesia After Total Hip Arthroplasty | 2026-12-01 |
| NCT07363096Ankara Etlik City HospitalSingle- Versus Two-Level ESP Block for Analgesia After Lumbar Stabilization Surgery | 2027-01-01 |
| NCT07739277Ankara Etlik City HospitalTransverse vs. Longitudinal Serratus Anterior Plane Block in Breast Surgery | 2027-02-08 |
| NCT07650591Akdeniz UniversityTHE EFFECT OF 'RHYTHMİC SKİN TAPPİNG' AND INTERNAL VİBRATİON APPLİED PROXİMAL TO THE PROCEDURE SİTE ON PAİN AND FEAR PERCEPTİON DURİNG PEDİATRİC PERİPHERAL VENİPUNCTURE | 2027-05 |
| NCT07841951Medipol UniversityTwo Bupivacaine Concentrations for Recto-Intercostal Fascial Plane Block After Laparoscopic Cholecystectomy | 2027-05-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 158 studies in Acute Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to evaluate the effect of the ShotBlocker device on pain, anxiety, and patient satisfaction during peripheral intravenous catheterization (PIVC). Peripheral intravenous catheterization is a commonly performed procedure in clinical settings and is often associated with pain and anxiety, which may negatively affect patient experience.
The ShotBlocker is a simple, non-pharmacological device designed to reduce pain by applying pressure and sensory stimulation at the injection site. Participants will be randomly assigned to either the intervention group, where the ShotBlocker will be used during the procedure, or the control group, where routine care will be provided.Pain will be assessed using the Visual Analog Scale (VAS). Anxiety and patient satisfaction will be evaluated using a visual analog-based scale supported , combining features of the Visual Analog Scale and the Wong-Baker Faces Scale, with scores ranging from 0 to 10. The findings of this study are expected to contribute to evidence-based nursing practices by providing an effective, low-cost, and non-invasive method for reducing procedural discomfort and improving patient experience during PIVC.
Peripheral intravenous catheterization (PIVC) is one of the most frequently performed invasive procedures in clinical practice. Despite its routine nature, it is commonly associated with pain and anxiety, which may negatively influence patient comfort, satisfaction, and overall experience of care. Therefore, effective and practical strategies to reduce procedure-related discomfort are essential in nursing practice.
The ShotBlocker is a simple, non-pharmacological device designed to reduce pain by applying mechanical pressure and providing sensory distraction at the injection site. It is inexpensive, easy to use, and does not require additional training or pharmacological intervention, making it suitable for routine clinical use.
This study is designed as a randomized controlled trial to evaluate the effectiveness of the ShotBlocker device during PIVC. Participants will be randomly assigned to either the intervention group, in which the ShotBlocker will be applied during the catheterization procedure, or the control group, in which routine care will be provided without any additional intervention.
Pain intensity will be assessed using the Visual Analog Scale (VAS). Anxiety and patient satisfaction will be evaluated using a visual analog-based scale supported by combining features of the Visual Analog Scale and the Wong-Baker Faces Scale, with scores ranging from 0 to 10.
All procedures will be performed by trained healthcare professionals following standard clinical protocols. Data will be collected immediately after the procedure. The primary outcome of the study is pain intensity, while secondary outcomes include anxiety and patient satisfaction.
The results of this study are expected to provide evidence for the effectiveness of a simple, non-invasive, and cost-effective method to reduce procedure-related discomfort and improve patient-centered care in clinical settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals aged 18 years and older Patients requiring peripheral intravenous catheterization Patients who are conscious and able to communicate Patients who agree to participate in the study and provide
Exclusion Criteria:
Patients with cognitive impairment or inability to communicate Patients with a history of chronic pain or current use of analgesics Patients with dermatological conditions or wounds at the catheterization site Patients who previously experienced peripheral intravenous catheterization within the last 24 hours Patients who refuse to participate in the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive peripheral intravenous catheterization using the ShotBlocker device during the procedure.
Device: ShotBlocker
Participants will receive routine peripheral intravenous catheterization without the use of the ShotBlocker device.
A non-pharmacological device applied to the skin to reduce pain through mechanical pressure and sensory stimulation during peripheral intravenous catheterization.
Pain Intensity During Peripheral Intravenous Catheterization
Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: Immediately after the procedure
Anxiety Level
Anxiety will be assessed using a visual analog scale with scores ranging from 0 to 10, both before and immediately after the procedure.
Time frame: Before and immediately after the procedure
Patient Satisfaction
Patient satisfaction will be assessed immediately after the procedure using a visual analog-based scale supported by , with scores ranging from 0 to 10.
Time frame: Immediately after the procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in May 2026, 1 month.
Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 1 month is below that.
Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kirsehir Ahi Evran Universitesi →